We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

13 hedge funds and large institutions have $138K invested in Ensysce Biosciences in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

19% less funds holding

Funds holding: 16 → 13 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

83% less capital invested

Capital invested by funds: $833K → $138K (-$695K)

Holders
13
Holders Change
-3
Holders Change %
-18.75%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
–
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$112K
2
Two Sigma Investments
Two Sigma Investments
New York
+$105K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$70.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$46.5K
5
Millennium Management
Millennium Management
New York
+$38K

Top Sellers

Rank Fund Capital Flow
1
HVCM
HG Vora Capital Management
New York
-$529K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$68K
3
Cerity Partners
Cerity Partners
New York
-$32K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$28K
5
MGIA
Moneta Group Investment Advisors
Missouri
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$31.7K +$112K +235 New
Two Sigma Investments
2
Two Sigma Investments
New York
$29.9K +$105K +222 New
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$19K +$70.3K +148 New
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$13.2K +$46.5K +98 New
Millennium Management
5
Millennium Management
New York
$11K +$38K +80 New
UBS Group
6
UBS Group
Switzerland
$10.4K +$29.9K +63 +450%
BlackRock
7
BlackRock
New York
$8.78K – – –
Stifel Financial
8
Stifel Financial
Missouri
$8.12K – – –
Bank of America
9
Bank of America
North Carolina
$4.54K +$16.1K +34 New
TRCT
10
Tower Research Capital (TRC)
New York
$1K – – –
Morgan Stanley
11
Morgan Stanley
New York
$207 +$950 +2 New
PMFA
12
Plante Moran Financial Advisors
Michigan
$186 +$475 +1 New
WAM
13
Wolverine Asset Management
Illinois
$112 – – –
Wells Fargo
14
Wells Fargo
California
$6 – – –
HVCM
15
HG Vora Capital Management
New York
– -$529K -684 Closed
Vanguard Group
16
Vanguard Group
Pennsylvania
– -$68K -88 Closed
Cerity Partners
17
Cerity Partners
New York
– -$32K -42 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$28K -36 Closed
Northern Trust
19
Northern Trust
Illinois
– -$11K -14 Closed
VF
20
Virtu Financial
New York
– -$9K -12 Closed
State Street
21
State Street
Massachusetts
– -$8K -10 Closed
TSS
22
Two Sigma Securities
New York
– -$7K -9 Closed
Jane Street
23
Jane Street
New York
– -$4K -6 Closed
SG
24
StoneX Group
New York
– -$2.75K -4 Closed
MGIA
25
Moneta Group Investment Advisors
Missouri
– -$22K -1 Closed

ENSC Hedge Fund Activity: Q4 2022 in Review

13 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q4 2022, worth a combined $138K — down 83% from $833K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ENSC and 8 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $112K. The largest seller was HG Vora Capital Management, exiting entirely with an estimated $529K sold.

  • 13 institutional investors held Ensysce Biosciences (ENSC) as of Q4 2022, down from 16 in Q3 2022.
  • Funds reported $138K of Ensysce Biosciences stock for Q4 2022, down 83% quarter-over-quarter.
  • 8 funds opened new Ensysce Biosciences positions in Q4 2022 and 11 closed out, a net change of -3 holders.
  • The largest Ensysce Biosciences buyer in Q4 2022 was Citadel Advisors, an estimated $112K added.
  • The largest Ensysce Biosciences seller in Q4 2022 was HG Vora Capital Management, an estimated $529K sold.

Based on aggregated 13F filings for Q4 2022.